Comprehensive Stock Comparison

Compare XOMA Corporation (XOMAP) vs BlackRock Technology and Private Equity Term Trust (BTX) Stock

Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.

Tickers 2 / 10100+ Metrics

Selected Stocks

Add up to 10 tickers. Use presets or search to get started.

2 / 10
Try these comparisons:

Quick Verdict

CategoryWinnerWhy
GrowthXOMAP logoXOMAP498.7% revenue growth vs BTX's -81.1%
ValueBTX logoBTXLower P/E (38.6x vs 39.1x)
Quality / MarginsBTX logoBTX87.7% net margin vs XOMAP's 46.1%
Stability / SafetyXOMAP logoXOMAPBeta 0.13 vs BTX's 1.16
DividendsBTX logoBTX13.1% yield, 1-year raise streak, vs XOMAP's 1.8%
Momentum (1Y)XOMAP logoXOMAP+9.2% vs BTX's +7.1%
Efficiency (ROA)XOMAP logoXOMAP8.3% ROA vs BTX's 1.8%, ROIC -37.6% vs 1.4%
Bottom line: XOMAP leads in 4 of 7 categories, making it the stronger pick for investors who prioritize growth and revenue expansion and capital preservation and lower volatility. BlackRock Technology and Private Equity Term Trust is the better choice for valuation and capital efficiency and profitability and margin quality. As direct sector peers, they can serve as alternatives in the same portfolio allocation.

Who Each Stock Is For

Income & stability

Growth exposure

Long-term compounding (10Y)

Sleep-well-at-night portfolio

Defensive / Recession hedge

Business Model

What each company does and how it makes money

XOMAPXOMA Corporation
Healthcare

XOMA Corporation is a biotechnology royalty aggregator that acquires future economic rights to pre-commercial therapeutic candidates licensed to pharmaceutical partners. It generates revenue primarily through milestone payments and royalties from its portfolio of approximately 70 early to mid-stage clinical assets — with no single asset dominating its income stream. The company's moat lies in its specialized expertise in evaluating and structuring royalty agreements for complex biotech assets, creating a diversified portfolio of potential future revenue streams.

BTXBlackRock Technology and Private Equity Term Trust
Healthcare

BlackRock Technology and Private Equity Term Trust is a closed-end investment fund that pools investor capital to invest primarily in mid- and small-capitalization growth companies in the technology and healthcare sectors. It generates returns through capital appreciation and dividend income from its equity portfolio, with performance tied to the success of its underlying investments. The fund's key advantage is BlackRock's extensive research capabilities and access to innovative companies that traditional investors might overlook.

Financial Metrics Comparison

Side-by-side fundamentals across 2 stocks. BestLagging

Financial Scorecard

BTX logoBTX 3XOMAP logoXOMAP 2
Financial MetricsBTX logoBTX4/4 metrics
Valuation MetricsXOMAP logoXOMAP2/3 metrics
Profitability & EfficiencyBTX logoBTX5/8 metrics
Total ReturnsXOMAP logoXOMAP5/6 metrics
Risk & VolatilityTie1/2 metrics
Analyst OutlookBTX logoBTX2/2 metrics

BTX leads in 3 of 6 categories (Financial Metrics, Profitability & Efficiency). XOMAP leads in 2 (Valuation Metrics, Total Returns). 1 tied.

Financial Metrics (TTM)

XOMAP and BTX operate at a comparable scale, with $47M and $41M in trailing revenue. BTX is the more profitable business, keeping 87.7% of every revenue dollar as net income compared to XOMAP's 46.1%.

MetricXOMAP logoXOMAPXOMA CorporationBTX logoBTXBlackRock Technol…
RevenueTrailing 12 months$47M$41M
EBITDAEarnings before interest/tax$13M
Net IncomeAfter-tax profit$22M
Free Cash FlowCash after capex$5M
Gross MarginGross profit ÷ Revenue+93.6%+100.0%
Operating MarginEBIT ÷ Revenue-15.0%+87.7%
Net MarginNet income ÷ Revenue+46.1%+87.7%
FCF MarginFCF ÷ Revenue+11.4%+6.8%
Rev. Growth (YoY)Latest quarter vs prior year+29.9%
EPS Growth (YoY)Latest quarter vs prior year+144.0%
BTX leads this category, winning 4 of 4 comparable metrics.

Valuation Metrics

MetricXOMAP logoXOMAPXOMA CorporationBTX logoBTXBlackRock Technol…
Market CapShares × price$321M$765M
Enterprise ValueMkt cap + debt − cash$338M$765M
Trailing P/EPrice ÷ TTM EPS-15.79x38.56x
Forward P/EPrice ÷ next-FY EPS est.39.12x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple21.43x
Price / SalesMarket cap ÷ Revenue11.26x18.80x
Price / BookPrice ÷ Book value/share3.72x0.79x
Price / FCFMarket cap ÷ FCF2.76x
XOMAP leads this category, winning 2 of 3 comparable metrics.

Profitability & Efficiency

XOMAP delivers a 20.1% return on equity — every $100 of shareholder capital generates $20 in annual profit, vs $2 for BTX. On the Piotroski fundamental quality scale (0–9), XOMAP scores 4/9 vs BTX's 3/9, reflecting mixed financial health.

MetricXOMAP logoXOMAPXOMA CorporationBTX logoBTXBlackRock Technol…
ROE (TTM)Return on equity+20.1%+1.9%
ROA (TTM)Return on assets+8.3%+1.8%
ROICReturn on invested capital-37.6%+1.4%
ROCEReturn on capital employed-19.4%+1.8%
Piotroski ScoreFundamental quality 0–943
Debt / EquityFinancial leverage1.46x
Net DebtTotal debt minus cash$18M$0
Cash & Equiv.Liquid assets$102M
Total DebtShort + long-term debt$119M$0
Interest CoverageEBIT ÷ Interest expense2.20x2313.25x
BTX leads this category, winning 5 of 8 comparable metrics.

Total Returns (with DRIP)

A $10,000 investment in XOMAP five years ago would be worth $14,545 today (with dividends reinvested), compared to $5,420 for BTX. Over the past 12 months, XOMAP leads with a +9.2% total return vs BTX's +7.1%. The 3-year compound annual growth rate (CAGR) favors XOMAP at 9.2% vs BTX's 5.5% — a key indicator of consistent wealth creation.

MetricXOMAP logoXOMAPXOMA CorporationBTX logoBTXBlackRock Technol…
YTD ReturnYear-to-date-1.9%-0.4%
1-Year ReturnPast 12 months+9.2%+7.1%
3-Year ReturnCumulative with dividends+30.2%+17.5%
5-Year ReturnCumulative with dividends+45.4%-45.8%
10-Year ReturnCumulative with dividends+51.6%-45.8%
CAGR (3Y)Annualised 3-year return+9.2%+5.5%
XOMAP leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

XOMAP is the less volatile stock with a 0.13 beta — it tends to amplify market swings less than BTX's 1.16 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.

MetricXOMAP logoXOMAPXOMA CorporationBTX logoBTXBlackRock Technol…
Beta (5Y)Sensitivity to S&P 5000.13x1.16x
52-Week HighHighest price in past year$30.00$7.50
52-Week LowLowest price in past year$24.96$5.10
% of 52W HighCurrent price vs 52-week peak+86.9%+87.4%
RSI (14)Momentum oscillator 0–10042.247.5
Avg Volume (50D)Average daily shares traded778791K
Evenly matched — XOMAP and BTX each lead in 1 of 2 comparable metrics.

Analyst Outlook

For income investors, BTX offers the higher dividend yield at 13.05% vs XOMAP's 1.79%.

MetricXOMAP logoXOMAPXOMA CorporationBTX logoBTXBlackRock Technol…
Analyst RatingConsensus buy/hold/sellBuy
Price TargetConsensus 12-month target
# AnalystsCovering analysts9
Dividend YieldAnnual dividend ÷ price+1.8%+13.1%
Dividend StreakConsecutive years of raises01
Dividend / ShareAnnual DPS$0.47$0.86
Buyback YieldShare repurchases ÷ mkt cap+0.0%+12.1%
BTX leads this category, winning 2 of 2 comparable metrics.

Historical Charts

Charts are rendered on first load. Hover for details.

Chart 1Total Return — 5 Years (Rebased to 100)

StockApr 21Mar 26Change
XOMA Corporation (XOMAP)100103.77+3.8%
BlackRock Technolog… (BTX)102.6532.74-68.1%

XOMA Corporation (XOMAP) returned +45% over 5 years vs BlackRock Technolog… (BTX)'s -46%. A $10,000 investment in XOMAP 5 years ago would be worth $14,545 today (including dividends reinvested).

Chart 2Revenue Growth — 10 Years

Stock20152024Change
XOMA Corporation (XOMAP)$55M$28M-48.6%
BlackRock Technolog… (BTX)$-640M$41M+106.4%

XOMA Corporation's revenue grew from $55M (2015) to $28M (2024) — a -7.1% CAGR.

Chart 3Net Margin Trend — 10 Years

Stock20152024Change
XOMA Corporation (XOMAP)-37.2%-48.5%-30.6%
BlackRock Technolog… (BTX)100.1%87.7%-12.4%

XOMA Corporation's net margin went from -37% (2015) to -49% (2024).

Chart 4EPS Growth — 10 Years

Stock20152024Change
XOMA Corporation (XOMAP)-1.82-1.65+9.3%
BlackRock Technolog… (BTX)-2.580.17+106.6%

XOMA Corporation's EPS grew from $-1.82 (2015) to $-1.65 (2024).

Chart 5Free Cash Flow — 5 Years

2021
$-4M
$-5B
2022
$-28M
$310M
2023
$-18M
$217M
2024
$-14M
$277M
XOMA Corporation (XOMAP)BlackRock Technolog… (BTX)

XOMA Corporation generated $-14M FCF in 2024 (-260% vs 2021). BlackRock Technology and Private Equity Term Trust generated $277M FCF in 2024 (+106% vs 2021).

Loading custom metrics...

XOMAP vs BTX: Frequently Asked Questions

7 questions · data-driven answers · updated daily

01

Is XOMAP or BTX a better buy right now?

BlackRock Technology and Private Equity Term Trust (BTX) offers the better valuation at 38.6x trailing P/E, making it the more compelling value choice. Analysts rate XOMA Corporation (XOMAP) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — XOMAP or BTX?

Over the past 5 years, XOMA Corporation (XOMAP) delivered a total return of +45.4%, compared to -45.8% for BlackRock Technology and Private Equity Term Trust (BTX). A $10,000 investment in XOMAP five years ago would be worth approximately $15K today (assuming dividends reinvested). Over 10 years, the gap is even starker: XOMAP returned +51.6% versus BTX's -45.8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — XOMAP or BTX?

By beta (market sensitivity over 5 years), XOMA Corporation (XOMAP) is the lower-risk stock at 0.13β versus BlackRock Technology and Private Equity Term Trust's 1.16β — meaning BTX is approximately 776% more volatile than XOMAP relative to the S&P 500.

04

Which has better profit margins — XOMAP or BTX?

BlackRock Technology and Private Equity Term Trust (BTX) is the more profitable company, earning 87.7% net margin versus -48.5% for XOMA Corporation — meaning it keeps 87.7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BTX leads at 87.7% versus -140.3% for XOMAP. At the gross margin level — before operating expenses — BTX leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

05

Which pays a better dividend — XOMAP or BTX?

All stocks in this comparison pay dividends. BlackRock Technology and Private Equity Term Trust (BTX) offers the highest yield at 13.1%, versus 1.8% for XOMA Corporation (XOMAP).

06

Is XOMAP or BTX better for a retirement portfolio?

For long-horizon retirement investors, XOMA Corporation (XOMAP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.13), 1.8% yield). Both have compounded well over 10 years (XOMAP: +51.6%, BTX: -45.8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

07

What are the main differences between XOMAP and BTX?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: XOMAP is a small-cap quality compounder stock; BTX is a small-cap income-oriented stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.

🚀
Stocks Like

XOMAP

High-Growth Quality Leader

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 27%
Run This Screen
🛡️
Stocks Like

BTX

Dividend Mega-Cap Quality

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 52%
  • Dividend Yield > 5.2%
Run This Screen
Custom Screen

Better Than Both

Find stocks that beat XOMAP and BTX on the metrics you choose

Net Margin>
%
(XOMAP: 46.1% · BTX: 87.7%)